SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese operator of aesthetic medical clinics and provider of consulting services, is making its first major move into the U.S. market through a strategic investment in OrangeTwist, a U.S.-based medspa chain specializing in non-invasive aesthetic treatments. The partnership, announced late last month, combines SBC's operational expertise with OrangeTwist's advanced management system and 24 locations across six states.
The medical aesthetics industry is projected to grow from $34 billion to $48 billion by 2030, driven by demand for non-surgical treatments such as injectables, fillers, and laser procedures. SBC estimates that the U.S. aging population—with 4.1 million people turning 65 each year through 2027—will further fuel demand. By partnering with OrangeTwist, SBC aims to address "white space" in underserved U.S. markets, opening new locations quickly and gaining first-mover advantages.
Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga that the company plans more strategic investments in the U.S. "As part of SBC’s global expansion, we are working hard to find local partnerships rather than copying and pasting what we did in Japan," Rodgers said in an interview. He emphasized that SBC seeks partners with aligned missions, leadership positions, and scalability.
Beyond the U.S., SBC is expanding in Japan and Southeast Asia, leveraging its one-stop management model to train staff, optimize pricing, and improve operations at affiliated clinics. The global anti-aging market, valued at approximately $85 billion in 2025, is expected to surpass $120 billion by 2030, according to Gabelli Research. North America accounts for 30% of that market, while Asia shows robust growth driven by beauty-conscious consumers and an aging population.
SBC's strategy rests on three pillars: partnering with high-performing regional operators, deploying expertise to drive efficiencies, and securing first-mover advantages. The company already manages over six million patient visits annually through 258 affiliated clinics worldwide. By standardizing services across Japan, Thailand, and Singapore, SBC ensures consistent quality and pricing.
The longevity industry is shifting from increasing lifespan to boosting "healthspan" through personalized, preventative, and tech-driven solutions. Key trends include AI-powered diagnostics, GLP-1 weight-loss drugs, and regenerative therapies. SBC believes its infrastructure positions it to offer these services cost-effectively.
In addition to joint operations, OrangeTwist and SBC plan to co-develop branded products and sell existing products in each other's spas. Healthcare-focused private equity firm Hildred Capital and Athyrium Capital are longstanding institutional shareholders in OrangeTwist, further supporting the partnership.
For more information on SBC Medical, visit their website. This content was originally published on Benzinga.
